Nanotechwert mit Hundefutter-Fantasie - 500 Beiträge pro Seite

[gem20]

LAM Pharmaceutical Expands Product Line by Introducing Veterinary Offering
Thursday January 15, 6:46 am ET

LEWISTON, N.Y., Jan. 15 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it has introduced an application for the veterinary industry. This application, incorporating L.A.M. Ionic Polymer Matrix(TM) technology, has demonstrated high efficacy in the treatment of pyotraumatic dermatitis and other skin ailments commonly suffered by dogs.

Recently published data suggests that nearly 32% of households in the United States own at least one dog, resulting in an estimated dog population of 53 million. New statistics also indicate that Americans spent approximately $31 billion on their pets in 2003. Pyotraumatic dermatitis, more commonly known as hot spots, and other skin ailments are among the most common ailments that require dogs to be examined and treated by a veterinarian.

"With the introduction of the veterinary application, LAM has demonstrated its ability to broaden the product offering and potentially access new revenue sources," stated Joseph Slechta, President and Chief Executive Officer of LAM.


"We are currently exploring opportunities to partner with veterinary suppliers
in order to distribute this application in the United States. Our product
will enhance the pet ownership experience by treating these common canine skin
aliments."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 14 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington
(Investors/Media)
646-536-7017
The Ruth Group



------------------------------------------------------------------------
Source: LAM Pharmaceutical, Corp.

[toptiper]

Der Chart sieht super aus - diese Supernews werden wohl zu einem Schub nach oben führen! Marktkapitalisierung nur 8 Mio + Lustmittel für die Ladies im Angebot - laut N-TV ist dieser Markt Milliardenschwer